News | ECG | October 13, 2023

InfoBionic Receives FDA 510(k) Clearance for its Next Generation MoMe ARC Solution

InfoBionic, the virtual telemetry company focused on efficiency and economics of cardiac remote patient monitoring, announces FDA 510(k) clearance for its MoMe ARC solution that encompasses our next generation remote ECG monitoring device and initial Bluetooth diagnostic 6-lead sensor designed to aid physicians in their diagnosis of cardiac arrhythmias. 

InfoBionic announces FDA 510(k) clearance for its MoMe ARC solution that encompasses our next generation remote ECG monitoring device and initial Bluetooth diagnostic 6-lead sensor designed to aid physicians in their diagnosis of cardiac arrhythmias

October 13, 2023 — InfoBionic, Inc. today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MoMe ARC, their 3rd Generation remote ECG monitoring device paired with their inaugural Bluetooth diagnostic 6-lead sensor designed to aid physicians in their diagnosis of cardiac arrhythmias in patients with a demonstrated need for cardiac monitoring. “We’re thrilled to announce FDA 510(k) clearance to market the MoMe ARC solution, which supports our mission to create superior patient monitoring solutions for arrhythmia detection and virtual care and chronic disease management,” said Dave MacCutcheon, Regulatory and Chief Operating Officer at InfoBionic. 

MacCutcheon further points out that “MoMe ARC is a solution that includes a 4-in-1 Gateway device that seamlessly transitions between 2-day in addition to Extended Holter tests, Event and MCT modes remotely, streamlining patient monitoring time and minimizing delays. In addition, MoMe ARC leverages a comprehensive cloud-based proprietary platform to deliver on-demand, actionable data and analytics directly to the clinicians. Further it incorporates our initial sleek body worn Sensor in a new lightweight form factor which is decoupled from the device Gateway communicating through the latest implementations of Bluetooth connectivity and ushers in a new era of wearability convenience yet maintains the ECG quality of a multi-lead tracing thus bringing convenience and quality together for the first time. The MoMe ARC is designed so patients can wear it discretely and comfortably during monitoring using standard electrodes. The Sensor is paired to the ARC Gateway which leverages a cellular connection to the MoMe Software Platform empowering physicians to transform the efficiency with which they manage cardiac arrhythmia detection and monitoring processes for their patients.” 

This next generation device builds on the market success of innovative MoMe Kardia II by providing a decoupled 2-channel – 6-Lead Sensor. Added foundational technologies make the device capable of connecting to other Bluetooth enabled health monitoring devices. K230265 is cleared for use under Product Code DSI - Arrhythmia Detector and Alarm (Including ST-Segment Measurement and Alarm). The ECG data is transmitted in near-real time and analyzed by the MoMe software platform via a suite of robust server-based algorithms; and when indicated, data identified by these algorithms is flagged for clinician review. MoMe ARC requires no patient intervention to capture or analyze data, however it does provide a patient event trigger and symptom description selection through a new screen similar to that of a smart watch. 

InfoBionic expects to begin shipping the new generation MoMe ARC Device in Q4 2023. 

For more information: www.infobionic.com


Related Content

News | FDA

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | FDA

July 29, 2024 — CorVascular, a leading producer of peripheral arterial disease (PAD) / peripheral vascular disease (PVD) ...

Home July 29, 2024
Home
News | FDA

July 2, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott has issued a correction for its ...

Home July 02, 2024
Home
News | FDA

June 18, 2024 — Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary ...

Home June 18, 2024
Home
News | FDA

June 17, 2024 — Elutia Inc., a pioneer in drug-eluting biomatrix products, today announced that its Antibiotic-Eluting ...

Home June 17, 2024
Home
News | FDA

June 13, 2024 — Xeltis, a leading developer of transformative implants that enable the natural creation of living and ...

Home June 13, 2024
Home
News | FDA

June 3, 2024 — Heuron, a specialized medical AI startup focused on brain and neurological disorders based in South Korea ...

Home June 03, 2024
Home
News | FDA

May 17, 2024 — Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has ...

Home May 17, 2024
Home
News | FDA

May 15, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling the HeartMate 3 LVAS by ...

Home May 15, 2024
Home
News | FDA

May 8, 2024 — The US Food and Drug Administration (FDA) is alerting health care providers and facilities about our ...

Home May 08, 2024
Home
Subscribe Now